Continuum Advisory LLC Boosts Position in CVS Health Corporation $CVS

Continuum Advisory LLC raised its holdings in shares of CVS Health Corporation (NYSE:CVS) by 11.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 76,148 shares of the pharmacy operator’s stock after buying an additional 7,639 shares during the period. Continuum Advisory LLC’s holdings in CVS Health were worth $5,741,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. Norges Bank purchased a new stake in CVS Health during the 2nd quarter worth $1,358,698,000. Invesco Ltd. lifted its stake in shares of CVS Health by 15.3% during the second quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock worth $1,623,270,000 after purchasing an additional 3,118,626 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its stake in shares of CVS Health by 815.2% in the second quarter. Robeco Institutional Asset Management B.V. now owns 2,663,111 shares of the pharmacy operator’s stock valued at $183,701,000 after buying an additional 2,372,121 shares in the last quarter. Kingstone Capital Partners Texas LLC purchased a new stake in shares of CVS Health during the 2nd quarter valued at about $155,185,000. Finally, Jennison Associates LLC lifted its position in CVS Health by 111.7% during the 2nd quarter. Jennison Associates LLC now owns 4,014,139 shares of the pharmacy operator’s stock worth $276,895,000 after acquiring an additional 2,117,798 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on CVS shares. Barclays lifted their price objective on shares of CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Leerink Partners lifted their price target on shares of CVS Health from $86.00 to $95.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Wells Fargo & Company decreased their price objective on shares of CVS Health from $103.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, November 13th. JPMorgan Chase & Co. lifted their target price on CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Finally, TD Cowen boosted their price target on CVS Health from $100.00 to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $94.67.

CVS Health Stock Up 0.4%

NYSE:CVS opened at $79.96 on Tuesday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.63 and a current ratio of 0.83. The company has a market capitalization of $101.50 billion, a price-to-earnings ratio of 210.41, a price-to-earnings-growth ratio of 0.79 and a beta of 0.48. CVS Health Corporation has a one year low of $43.65 and a one year high of $85.15. The stock has a 50-day simple moving average of $78.86 and a 200 day simple moving average of $73.11.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.24. The firm had revenue of $102.87 billion for the quarter, compared to analysts’ expectations of $98.85 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.CVS Health’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Sell-side analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.